Perampanel as first add-on choice on the treatment of mesial temporal lobe epilepsy: an observational real-life study.
Neurol Sci
; 42(4): 1389-1394, 2021 Apr.
Article
em En
| MEDLINE
| ID: mdl-32772278
ABSTRACT
PURPOSE:
To evaluate the efficacy of perampanel (PER) in patients with a diagnosis of mesial temporal lobe epilepsy (MTLE) taking PER as first add-on option due to inefficacy of first antiepileptic drug (AED), rather than late add-on choice.METHODS:
Thirty-seven MTLE patients aged ≥ 12 years were recruited consecutively with a minimum duration of follow-up of 1 year and intermediate follow-up of 3 months. Patients were divided into two groups 20/37 taking PER as first add-on due to inefficacy of first AED (first group) and 17/37 taking PER as late add-on due to inefficacy of ≥ 2 AEDs (second group). Efficacy, retention rate, and safety were evaluated.RESULTS:
At 3 months, the 70% of the first group had a reduction > 50% of seizure frequency, with six patients becoming also seizure free, while in the second group, only the 23.5% had a reduction > 50% of seizure frequency and none became seizure free (p = 0.005). Six patients of first group were also switched to a monotherapy of PER and five out of six remained seizure free at 12 months. At 1 year of follow-up, efficacy of PER was 70% for the first group, while only of 29.4% for the second group (p = 0.014). Retention rate of the first group at 3 months and 1 year was 85%, while for the second group was, respectively, 82.3% and 64.7%.CONCLUSION:
PER was significantly successful and tolerated in MTLE patients when used as first add-on option rather than as late add-on.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Epilepsia do Lobo Temporal
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Itália